Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2. fázis

Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency

A legfontosabb adatok

Ki végzi
Seattle Institute for Biomedical and Clinical Research
Hol
Augusta, Boston és Seattle (Egyesült Államok)Mind a 3 helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Fázis
2. fázis
Résztvevők
230 fő, tervezett
Kezdés
2021. jan. 12.
Várható befejezés
2026. nov.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • testosterone 1.62% gel
  • placebo gel
A regiszteradat frissítve
2026. július 6.

Ki vehet részt

Életkor
55 év felett
Nem
Csak férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 19 feltétel megnézéseKevesebb

Ki vehet részt

  • Men with active solid or hematologic (blood) cancers who have received or are receiving chemo- and/or radiation therapy. Patients who have no evidence of disease (NED) for 60 months or less, which means that they are <60 months from their last treatment (chemotherapy and/or radiation therapy) will be included
  • Age: 55 years and older
  • Life expectancy of at least 6 months
  • Serum testosterone, measured by mass spectrometry (gold standard method), of <348 ng/dl and/or free testosterone <70 pg/ml. The lower limits of the normal range for total testosterone in healthy men is 348 ng/dL and the lower limits of free testosterone is <70 pg/ml in the Framingham Heart Study sample. As sex hormone binding globulin levels may be elevated in some men with cancer (resulting in elevation in total testosterone level), some of these symptomatic men may still be hypogonadal despite having total testosterone above this cut-off limit, but their free testosterone levels may still be below the lower limit of normal. Thus, men with free testosterone <70 pg/mL will be included
  • Fatigue. Fatigue was selected as it is a highly prevalent symptom in cancer patients. Fatigue will be defined as a score on FACIT-Fatigue subscale of <40, which best divides cancer patients from the general population with accuracy
  • Ability and willingness to provide informed consent

Ki nem vehet részt

  • Men with current or prior history of prostate, breast, testicular, or adrenal cancers
  • Previous stroke with residual cognitive or functional deficits
  • Uncontrolled congestive heart failure
  • Myocardial infarction, acute coronary syndrome, revascularization surgery, stroke or thromboembolism (of any etiology) within 6 months
  • Known history of thrombophilia due to a genetic mutation (e.g. Factor V Leiden)
  • Bipolar disorder or schizophrenia
  • Hematocrit >48%, serum creatinine >2.5 mg/dL
  • Poorly controlled diabetes as defined by hemoglobin A1c >10.0%
  • Use of anabolic agents (testosterone, DHEA, growth hormone) within the past 6 months
  • PSA >4 ng/ml; nodule or induration on digital rectal exam
  • Severe untreated sleep apnea
  • Inability to provide informed consent; MMSE score <24
  • Body mass index (BMI) >40 kg/m2

Helyszínek itt: Egyesült Államok

  • Georgia Cancer Center at Augusta UniversityAugusta, Egyesült Államok
  • Brigham and Women's HospitalBoston, Egyesült Államok
  • Veterans Affairs Puget Sound Health Care SystemSeattle, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer who report fatigue and have low testosterone levels.

A vizsgálat 2 csoportja

  • testosterone 1.62% gelA vizsgált kezelés

    Testosterone 1.62% gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.

  • placebo gelPlacebo, összehasonlításként

    The placebo gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. július 6.